Work

Resistance to antibody‐drug conjugates in breast cancer: mechanisms and solutions

Year: 2022

Type: article

Abstract: Antibody-drug conjugates (ADCs) are a rapidly developing therapeutic approach in cancer treatment that has shown remarkable activity in breast cancer. Currently, there are two ADCs approved for the treatment of human epidermal growth factor receptor 2-positive breast cancer, one for triple-negative breast cancer, and multiple investigational ADCs in clinical trials. However, drug resistance has been noticed in clinical use, especially in trastuzumab emtansine. Here, the mechanisms of ADC resistance are summarized into four categories: antibody-mediated resistance, impaired drug trafficking, disrupted lysosomal function, and payload-related resistance. To overcome or prevent resistance to ADCs, innovative development strategies and combination therapy options are being investigated. Analyzing predictive biomarkers for optimal therapy selection may also help to prevent drug resistance.

Source: 癌症：英文版

DOI: 10.1002/cac2.12387

Authors: Yu‐Fei Chen, Ying‐ying Xu, Zhi‐Ming Shao, Ke‐Da Yu

Institutions: Shanghai Medical College of Fudan University, Fudan University, Fudan University Shanghai Cancer Center, First Hospital of China Medical University

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,800